Volume 109, Current Issue
Vol 28, October 2019
Vol 27, September 2019
Vol 26, August 2019
Vol 25, July 2019
Vol 24, June 2019
Vol 23, May 2019
Vol 22, April 2019
Vol 21, March 2019
Vol 20, February 2019
Vol 19, January 2019
Vol 18, December 2018
Vol 17, November 2018
Vol 16, October 2018
Vol 15, September 2018
Vol 14, August 2018
Vol 13, July 2018
Vol 12, June 2018
Vol 11, May 2018
Vol 10, April 2018
Vol 9, March 2018
Vol 8, February 2018
Vol 7, January 2018
Vol 6 No 12, December 2017
Vol 6 No 11, November 2017
Vol 6 No 10, October 2017
Vol 6 No 9, September 2017
Vol 6 No 8, August 2017
Vol 6 No 7, July 2017
Vol 6 No 6, June 2017
Vol 6 No 5, May 2017
Vol 6 No 4, April 2017
Vol 6 No 3, March 2017
Vol 6 No 2, February 2017
Vol 6 No 1, January 2017
Vol 5 No 12, December 2016
Vol 5 No 11, November 2016
Vol 5 No 10, October 2016
Vol 5 No 9, September 2016
Vol 5 No 8, August 2016
Vol 5 No 7, July 2016
Vol 5 No 6, June 2016
Vol 5 No 5, May 2016
Vol 5 No 4, April 2016
Vol 5 No 3, March 2016
Vol 5 No 2, February 2016
Vol 5 No 1, January 2016
Vol 4 No 12, December 2015
Vol 4 No 11, November 2015
Vol 4 No 10, October 2015
Cover Story Current Issue

Epidemiological evidences provide proof of concept that certain pesticides are involved in metabolic disorders, but also in the pathophysiology of Parkinson's disease (PD). In addition, large prospective cohort studies reported that type 2 diabetes (T2D) and PD are epidemiologically associated, including an elevated risk of developing PD in patients with T2D.
Current Issue
Identifying targetable metabolic dependencies across colorectal cancer progression
- Abstract
Identifying targetable metabolic dependencies across colorectal cancer progression
Colorectal cancer (CRC) is a multi-stage process initiated through the formation of a benign adenoma, progressing to an invasive carcinoma and finally metastatic spread. Tumour cells must adapt their metabolism to support the energetic and biosynthetic demands associated with disease progression. As such, targeting cancer cell metabolism is a promising therapeutic avenue in CRC. However, to identify tractable nodes of metabolic vulnerability specific to CRC stage, we must understand how metabolism changes during CRC development. Here, we use a unique model system – comprising human early adenoma to late adenocarcinoma. We show that adenoma cells transition to elevated glycolysis at the early stages of tumour progression but maintain oxidative metabolism. Progressed adenocarcinoma cells rely more on glutamine-derived carbon to fuel the TCA cycle, whereas glycolysis and TCA cycle activity remain tightly coupled in early adenoma cells. Adenocarcinoma cells are more flexible with respect to fuel source, enabling them to proliferate in nutrient-poor environments. Despite this plasticity, we identify asparagine (ASN) synthesis as a node of metabolic vulnerability in late-stage adenocarcinoma cells. We show that loss of asparagine synthetase (ASNS) blocks their proliferation, whereas early adenoma cells are largely resistant to ASN deprivation. Mechanistically, we show that late-stage adenocarcinoma cells are dependent on ASNS to support mTORC1 signalling and maximal glycolytic and oxidative capacity. Resistance to ASNS loss in early adenoma cells is likely due to a feedback loop, absent in late-stage cells, allowing them to sense and regulate ASN levels and supplement ASN by autophagy. Together, our study defines metabolic changes during CRC development and highlights ASN synthesis as a targetable metabolic vulnerability in later stage disease.
Articles in Press
Identifying targetable metabolic dependencies across colorectal cancer progression
- Abstract
Identifying targetable metabolic dependencies across colorectal cancer progression
Colorectal cancer (CRC) is a multi-stage process initiated through the formation of a benign adenoma, progressing to an invasive carcinoma and finally metastatic spread. Tumour cells must adapt their metabolism to support the energetic and biosynthetic demands associated with disease progression. As such, targeting cancer cell metabolism is a promising therapeutic avenue in CRC. However, to identify tractable nodes of metabolic vulnerability specific to CRC stage, we must understand how metabolism changes during CRC development. Here, we use a unique model system – comprising human early adenoma to late adenocarcinoma. We show that adenoma cells transition to elevated glycolysis at the early stages of tumour progression but maintain oxidative metabolism. Progressed adenocarcinoma cells rely more on glutamine-derived carbon to fuel the TCA cycle, whereas glycolysis and TCA cycle activity remain tightly coupled in early adenoma cells. Adenocarcinoma cells are more flexible with respect to fuel source, enabling them to proliferate in nutrient-poor environments. Despite this plasticity, we identify asparagine (ASN) synthesis as a node of metabolic vulnerability in late-stage adenocarcinoma cells. We show that loss of asparagine synthetase (ASNS) blocks their proliferation, whereas early adenoma cells are largely resistant to ASN deprivation. Mechanistically, we show that late-stage adenocarcinoma cells are dependent on ASNS to support mTORC1 signalling and maximal glycolytic and oxidative capacity. Resistance to ASNS loss in early adenoma cells is likely due to a feedback loop, absent in late-stage cells, allowing them to sense and regulate ASN levels and supplement ASN by autophagy. Together, our study defines metabolic changes during CRC development and highlights ASN synthesis as a targetable metabolic vulnerability in later stage disease.
Registration & Abstract Submission are open!

13th
Helmholtz Diabetes Conference
Munich, 21-23. Sep 2026
2024 impact factor: 6.6
You are what you eat
Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.






































































